ABSTRACT-Pharmacokinetic (PK) data for antithrombin III (AT) are limited in the critical patients. We therefore performed PK analysis using a two-compartment model and also examined whether plasma AT activity would change depending on two administration methods, AT agent at 500 U/8 h (divided group) or 1,500 U/24 h (combined group) for 3 days, a regulated dosage for disseminated intravascular coagulation (DIC) treatment in Japan, in critical patients with DIC. Clinical prospective randomized study. A high care unit in a university hospital. Twenty-four consecutive critical patients with DIC. Ages ranged from 34 to 91 years. Acute physiology age and chronic health evaluation II scores were 25 to 35. Antithrombin III activities in the combined group caused remarkable transient increases but returned to near the preadministration level 24 h after the infusion. Antithrombin III level in the divided group showed small elevations on each session; therefore, steady increases were found after serial administrations of the agent. On the third day, AT trough activities in the divided group were significantly higher than those in the combined group (P = 0.005). However, peak AT activities in the combined group after AT administration were higher than those in the divided group throughout the study (P = 0.024). Aggravation of bleeding tendency occurred more frequently in the combined group (P = 0.03). Half-life times on the distribution phase in both groups were remarkably shorter than those of previously reported control in congenital AT deficiency. This suggests an increased vascular permeability in the critical patients in this study. Distribution volume in the patients here increased significantly as compared with the previous controls. This is the first PK report using a twocompartment model to demonstrate that remarkable increases in vascular permeability and distribution volume occur in critical patients with DIC, and if the same dose is administered intermittently in such PK situation, AT administration in divided manner can maintain plasma AT trough activity higher than that in the combined method.
INTRODUCTION
It is reported that elevating antithrombin III (AT) activity beyond its physiological range is required to obtain anticoagulatory and anti-inflammatory effects in septic patients with disseminated intravascular coagulation (DIC) (1, 2) . In recent subgroup analyses for KyberSept trail, high-dose AT has been demonstrated to be potentially beneficial in improving the outcome of septic patients with DIC (3, 4) . A large amount of AT agent, a daily 6,000 U used in the trial, achieved a high level of AT activity, but there, bleeding tendency would be a concern in such patients with severe platelet depletion (2) .
There are several pharmacokinetic (PK) studies on AT metabolism in congenital AT deficiency patients or normal volunteers (5, 6) . On the other hand, there is a PK paper using a one-compartment model in septic patients (1), although it is well known that AT distributes not only intravascular but also extravascular spaces (7) , which leads us to select a twocompartment model for PK study. Thus, the PK data for AT in the critical patients are still limited. Furthermore, it remains uncertain in such patients whether AT activity would be different depending on administration methods. Therefore, in this study, we performed PK analysis to determine whether AT agent at 500 U three times a day (divided group) or at 1,500 U just once per day (combined group) for 3 days, a regulated dosage for DIC treatment in Japan (8) , is more effective for maintaining AT trough activity in critical patients with DIC. Although still controversial, maintaining plasma AT trough levels in DIC patients is presumed important for obtaining antithrombin effects of AT (9) . We also examined differences in the rate of aggravation of bleeding tendency between the divided and combined groups.
MATERIALS AND METHODS

General
Twenty-four consecutive critical patients diagnosed as DIC were included in this study. The female/male ratio was 7/17. Ages ranged from 34 to 91 years. Acute Physiology and Chronic Health Evaluation II scores shortly before AT administration were 25 to 35 (Table 1) . Antithrombin III agent (ZLB-Bering, Tokyo, Japan) was randomly administered at 500 U three times per day or 1,500 U once per day for 3 days. Total dosage of the AT agent adhered to the recommendation of the government-run Health Care Insurance System in Japan (8) . Anticoagulants such as heparin, gabexate mesilate, or nafamostat mesilate were prohibited in all patients. Other treatments such as antibiotic administration, fluid infusion, and cardiovascular and respiratory support were decided by each physician in charge. After the 3-day treatment period, patients were followed until discharge from the hospital. Patients with hepatic failure (n = 4) or those whose aggressive therapies were being discontinued (n = 5) were excluded before including in this study. This study was approved to perform by the Ethics Committee of Ehime University Hospital, and informed consent was obtained.
Patient selection
Patients were enrolled when they were diagnosed as both DIC and had AT levels less than 70%. They were administered AT agent as soon as possible. This AT administration protocol adhered to our department regulations. Diagnosis for DIC was done based on the criteria proposed by the Research Committee on DIC of the Japanese Ministry of Health and Welfare (Table 2 , ref. (10)). On determination of DIC diagnosis, there were 18 sepsis patients among the 24 subjects in this study (Table 1) . Sepsis criteria were as follows (11): (1) clinical evidence of sepsis with a suspected origin of infection; (2) leukocyte count of 910,000/mm 3 or G3,500/mm 3 ; (3) body temperature (rectal or blood) of 938.5-C or G35.5-C. In addition, three of the following six signs are required: tachycardia more than 100 beats per minute; tachypnea more than 24 breaths per minute or mechanical ventilation; hypotension of systolic blood pressure less than 90 mmHg in the absence of administration of vasoactive agents or fluid resuscitation; thrombocytopenia less than 100,000/mm 3 ; elevated lactate levels more than 1.6 mM or metabolic acidosis (pH G7.3 or base excess ej10 mM) not secondary to respiratory alkalosis; oliguria with urine output less than 20 mL/h. 
Measurement for AT antigen and activity
Plasma AT antigen and activity were measured by a latex agglutination method (NS auto-AT kit, Naska Corp., Tokyo, Japan; Bio-majesty analyzer, Nihon Denshi Corp., Tokyo, Japan) and a synthesized substrate assay (Test-team S kit for AT, Dai-ichi Kagaku Corp., Tokyo, Japan; CA 7000 analyzer, Sysmexs, Tokyo, Japan), respectively. The normal range for each test is as follows: AT antigen, 17 to 30 mg/dL; AT activity, 70% to 110%.
Comparisons in peak and trough AT activities between the groups
We examined the differences in peak and trough AT activities between the combined and divided groups. All peak AT activities were collected for comparisons in the two groups until the third day after the initiation of AT administration. Trough AT activities were evaluated on the third day in both groups. We chose AT trough activity data on the third day for the comparison because plasma AT trough activity would be stable on the third day (12) . Although controversial, maintaining plasma AT trough levels in DIC patients is presumed important for obtaining antithrombin effects of AT (9) .
Comparisons in the rate of aggravation of bleeding tendency between the groups
The rate of bleeding was evaluated by gathering data from nursing check lists. The checks were strictly and routinely done three times a day by at least two independent and well-trained nurses who were not aware of the current study being performed. The checked points were as follows. (1) Is there any expansion of subcutaneous bleeding or petechia? (2) Are there any bloody sputums or pharyngeal secretions on intratracheal or oral suctions? (3) Is there any increase in bleeding from puncture sites for central venous catheters? (4) Is there any deterioration of bleeding sources that existed before AT administration? (5) Is there any increase in bleeding from wounds? Among the above points, when the nurses found even one positive sign in a patient (e.g., an increased area in subcutaneous bleeding), we counted one subject in the group as showing aggravation of bleeding tendency. The numbers of patients whose bleeding tendency worsened in the two groups were compared using a chi-square test.
PK analysis for AT
Antithrombin III activities were measured from plasma samples taken on preinfusion and at 30, 60, 120, and 180 min after the initiation of the agent in nine patients who were randomly selected from among those enrolled in this study. Antithrombin III was infused for 60 min. Because we observed a biphasic decay curve after AT administration in a preliminary study (Fig. 1A) , we selected a twocompartment model for this study. MULTI (13), a nonlinear least-square method program, was used with an NEC PC-9801 computer (Tokyo, Japan) for the analyses. Unit/Antigen ratio of AT agent used in this study was 6.3 T 0.1 IU/mg (14) . Antithrombin III concentrations of all samples in this study were assessed through activity (%) and antigen concentrations (milligrams per deciliter). Antithrombin III activities and antigen levels were correlated well (n = 120, r 2 = 0.91, P = 0.0001; Fig. 1C ). Therefore, PK evaluations were done by AT activity data. Using such relations, we calculated PK parameters of the AT agent. As a control, we selected data from a previous paper regarding AT PK analysis in congenital AT deficiency (5) . This previous article showed all data for changes in AT activities and antigen levels for each patient, thereby enabling us to compare statistically such data with our present data. Furthermore, another previous paper regarding AT metabolism in congenital deficiency patients and normal volunteers reported similar half-life times on the distribution and elimination phases in the two conditions (6) .
Statistical analysis
Data are expressed as mean T SD. Mann-Whitney U test, chi-square test, or Spearman correlation coefficient analysis was used for statistical analysis of the data. A P value less than 0.05 was considered significant.
RESULTS
Parameters, including coagulatory variables before AT administration, are depicted in Table 3 . There were no significant differences in the parameters before AT administration between the groups.
Comparisons of PK data between congenital and acute disease groups (nine patients who were randomly selected from all patients enrolled in this study) are shown in Table 4 . Half-life time of distribution phase in acute disease patients was significantly shorter than that in the congenital AT deficiency group, whereas half-life time of elimination phases did not differ. Distribution volume in the acute disease group was remarkably inflated as compared with that of the congenital group. Figure 1A and B shows typical recordings of AT activity changes after the two administration methods. As depicted in Figure 1A , 1,500 U of AT infusion caused remarkable transient increases in the activity, followed by a return to the level near the preadministration level. However, as shown in Figure 1B , 500 U of the agent produced small elevations in AT activity, which was followed by steady increases after several serial administrations of the agent. Figure 1C denotes quite well correlations between AT antigen and activity.
FIG. 1.
A and B, Typical recordings of AT activity changes after the two administration methods. A single dose of 1,500 U of AT infusion caused a remarkable transient increase in the activity but was followed by a return to near the preadministration level (A). However, 500 U of the agent three times a day produced small elevations in AT activity, which was followed by steady increases after serial administrations of the agent (B). Correlations between AT antigen and activity (C). Figure 2A denotes the time-course changes in AT activity after AT administration in both groups. Summarized data of AT trough activity on the third day of administration in the combined and divided groups are given in Figure 2B . Although there were no significant differences in AT activity between the two groups before AT administration, the trough levels of the divided group on the third day were significantly higher than those in the combined group. Figure 3A shows the differences in the rate of occurrence of aggravation of bleeding tendency between the two groups. The rate of such aggravation in the combined group was significantly higher than that in the divided group. Figure 3B compares AT peak levels during AT treatment in both groups. As shown in the figure, the peak levels in the combined group were significantly higher than those in the divided group. Figure 3C compares coagulatory parameters in both groups. There were no significant differences between the divided and combined groups.
DISCUSSION
PK analysis in acute patients with DIC
There has been very limited data regarding PK for AT agent especially in patients with acute disease. A possible explanation for the limited PK data is that endogenously produced AT should be taken into account in the analysis of PK data. Thus, a precise PK study should be done using AT agents with isotope labeling, which would be difficult in clinical settings.
Using a one-compartment model, a previous article demonstrated relative increases in both vascular permeability and distribution volume in sepsis patients (1) . However, it is well known that AT distributes to the intravascular and extravascular spaces (7) . Thus, we need to select a two-compartment PK model for AT study. In addition, we demonstrated that AT activity showed a biphasic decay curve after AT administration (Fig. 1A) . In such a situation, we have clearly demonstrated that in acute disease patients, distribution halflife times were significantly shorter than those of previous controls with congenital AT deficiency, suggesting an increased vascular permeability in the critical patients in this study. In addition, the distribution volume in the acute disease patients here increased significantly as compared with the previous controls. These changes in the PK profile in the acute patients probably contributed to the present results that the divided administration, in which the AT agent was administered at shorter, more frequent intervals, sustains the levels of AT trough activity more than the combined administration with longer intervals.
Regarding the shortened distribution phase of administered AT, possible causative factors can be raised as follows: (1) augmentation of AT consumption, which may be reflected in increased thrombin-antithrombin complex; and (2) increased vascular permeability, leading to AT leakage to the extravascular space. However, several studies, including our recent article, have indicated that heightened vascular permeability, but not augmented AT consumption, may play a major role in AT reduction during DIC (12, 15) . 
Determination of AT doses in acute patients with DIC
It is reported that substituted AT doses for patients can be calculated by the formula (100 j AT activity [%]) Â body weight (in kilograms), which was constructed using a relation that 1 U/kg of given AT should increase AT activity 1% (16) . However, this calculation does not include the concept of relapse time after the injection of AT agent. Furthermore, there was no consideration of the enhanced vascular permeability as indicated in this study. As demonstrated clearly in this study (Fig. 1A and the upper panel in Fig. 2A) , even if 3,000 U of AT, as calculated by the formula (16), were administered, AT activity increased transiently but was not sustained at the physiological range even 48 h after the initial injection. Therefore, it is unlikely that such a calculation formula is useful for determining the substituted dose of AT agent in such acute patients with DIC having shortened halflife time and increased distribution volume, as presented in this study.
Effective AT administration in critical patients with DIC
There is a previous study performing PK analysis for AT agent in septic patients with DIC (1) in which two methods were tested: (1) a 6,000-U bolus injection of AT agent followed by an intermittent 1,000-U administration every 4 h for 4 days; (2) the same first bolus infusion followed by continuous AT administration at 250 U/h for the same period. Both methods sustained AT activities even from 30 min after the treatment, which lasted until the end of study. In this   FIG. 2 . A, The time-course changes in AT activities after AT administration in each group. B, Summarized data of AT trough activity on the third day of administration in the combined and divided groups. Although there were no significant differences in AT activity between the two groups before AT administration, the trough levels of the divided group on the third day (48 h after AT administration) were significantly higher than those in the combine group. PRE-AD, preadministration; POST-AD, postadministration (48 h after AT administration).
FIG. 3.
A, The differences in the rate of occurrence of aggravation of bleeding tendency between the two groups. The rate of such deterioration in the combined group was significantly higher than that in the divided group. B, Comparison of AT peak levels during AT treatment in both groups. As shown in the figure, the peak levels in the combined group were significantly higher than those in the divided group. C, Comparisons of coagulatory parameters in both groups after AT administration. There were no significant differences in the parameters between the divided and combined groups after AT administration on the third day.
previous article, using a one-compartment model of PK, relative reduction in elimination period and increase in distribution volume were reported. Because AT distributes both in the intravascular and extravascular spaces (7), a twocompartment model should be used on PK analysis for AT. The tendencies in the PK parameters reported in the previous article (1) were demonstrated much more clearly in the present study using a two-compartment model.
It can be easily expected in the previous study (1) that such a large dose of AT maintained a high level beyond the physiological range of AT activity even in DIC patients with increased vascular permeability and inflated distribution volume. We have clearly demonstrated in this study that in DIC patients with a similar PK profile as the previous study, divided AT administration (500 U three times a day for 3 days) sustains AT activity within a physiological range and at a higher trough activity on the third day as compared with that by the combined method (1,500 U once a day for the same period). Thus, in DIC patients with heightened vascular permeability and inflated distribution volume, if the same dose is administered intermittently, we need to give AT agent in a divided manner to maintain AT trough activity. One might speculate that a continuous administration of AT agent is an ideal method to maintain AT trough activity. However, from the PK view, it seems difficult to obtain PK data for a two-compartment model during the continuous infusion of AT. Nonetheless, in the future, a bolus injection followed by the continuous infusion of AT agent should be tested in critical patients with similar PK profile as presented in this study.
Differences in aggravation of bleeding tendency between the two groups
In this study, we have demonstrated that the rate of aggravation of bleeding tendency in the combined group receiving 1,500 U of AT once a day was much higher than that of the divided group receiving 500 U three times a day. Furthermore, in the combined group, peak levels of AT activity during the treatment were significantly higher than those in the divided group (115% T 15% in the combined vs. 84% T 21% in the divided groups). It is reported that high doses of AT administration maintaining its activity from 150% to 200% aggravate bleeding tendency in sepsis patients with DIC (1, 2). Because AT has anticoagulatory effects (17), it is not surprising that AT elevation beyond the physiological range or abrupt AT increases might cause bleeding in DIC patients with bleeding tendency. In this study, there were no significant changes in coagulatory parameters after AT treatment in either group (Fig. 3C) . Therefore, it can be speculated that differences in the peak AT activity during the treatment are a responsible factor for worsening in bleeding tendency in the combined group. High-dose AT protocol aims to obtain not only antithrombotic but also anti-inflammatory effects (1, 2) . A recent preliminary paper showed that AT repletion within the physiological range decreases D-dimer and potentially brings a trend of favorable outcome in septic patients with DIC (17) , which may imply the importance of the antithrombotic properties of AT and the feasibility of AT repletion to the normal level. Also, from the viewpoint of the bleeding tendency, we should give preference to the divided method of administration to prevent aggravation of bleeding tendency in patients with DIC.
There are no reports examining whether trough or peak AT activity is important for exerting antithrombin and/or antiinflammatory effects of AT agent. However, one might speculate that plasma AT trough activity or constant AT levels may be required for its antithrombotic effects because plasma AT activity within normal ranges of 70% to 100% is needed for physiological antithrombin effects. Thus, it is likely that maintaining trough rather than peak AT activity is important for obtaining stable antithrombin effects in critical patients with DIC.
Limitations of the study
This study is limited in the variety of the diseases and number of patients. However, all patients in this study were complicated with DIC. Twenty-four patients with the criteria were enrolled consecutively, and patients were divided randomly into the divided and combined groups. There were no significant differences in the number of septic patients between the two groups, nor did other parameters differ before AT administration. Thus, it is likely that the data in the two groups can be comparable.
We applied data from a previous paper regarding AT PK analysis in the congenital AT deficiency in nonacute state (5) . In this previous article, all data for AT changes both in activities and antigen levels were shown, which enabled us to compare our data with those in the previous article. Although this previous paper was published approximately 20 years ago, the measurement methods for AT levels are the same as those used in this article. Furthermore, a two-compartment model, a requisite for PK analysis for AT, was used in the previous article, which can be a factor of choice. However, in the demographic data, there was a difference in ages between the acute disease and congenital deficiency groups (Table 3) . Therefore, further research is needed to clarify any agedependent changes, such as a possible metabolic deterioration for the agent, in the PK character of AT agent.
In conclusion, using a two-compartment model, this is the first PK report to demonstrate that remarkable increases in vascular permeability and distribution volume occur in critical patients with DIC, and if the same dose is administered intermittently in such PK situation, AT administration in divided manner can maintain plasma AT trough activity higher than that in the combined method.
